JP2010513539A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513539A5
JP2010513539A5 JP2009542980A JP2009542980A JP2010513539A5 JP 2010513539 A5 JP2010513539 A5 JP 2010513539A5 JP 2009542980 A JP2009542980 A JP 2009542980A JP 2009542980 A JP2009542980 A JP 2009542980A JP 2010513539 A5 JP2010513539 A5 JP 2010513539A5
Authority
JP
Japan
Prior art keywords
seq
heavy chain
light chain
amino acid
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009542980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513539A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/078568 external-priority patent/WO2008079466A1/en
Publication of JP2010513539A publication Critical patent/JP2010513539A/ja
Publication of JP2010513539A5 publication Critical patent/JP2010513539A5/ja
Pending legal-status Critical Current

Links

JP2009542980A 2006-12-20 2007-09-14 抗体とその製造法および使用法 Pending JP2010513539A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87106906P 2006-12-20 2006-12-20
PCT/US2007/078568 WO2008079466A1 (en) 2006-12-20 2007-09-14 Antibodies and methods for making and using them

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013169145A Division JP2014028812A (ja) 2006-12-20 2013-08-16 抗体とその製造法および使用法

Publications (2)

Publication Number Publication Date
JP2010513539A JP2010513539A (ja) 2010-04-30
JP2010513539A5 true JP2010513539A5 (enExample) 2010-09-30

Family

ID=39536929

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009542980A Pending JP2010513539A (ja) 2006-12-20 2007-09-14 抗体とその製造法および使用法
JP2013169145A Pending JP2014028812A (ja) 2006-12-20 2013-08-16 抗体とその製造法および使用法
JP2015056137A Pending JP2015145394A (ja) 2006-12-20 2015-03-19 抗体とその製造法および使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013169145A Pending JP2014028812A (ja) 2006-12-20 2013-08-16 抗体とその製造法および使用法
JP2015056137A Pending JP2015145394A (ja) 2006-12-20 2015-03-19 抗体とその製造法および使用法

Country Status (10)

Country Link
US (3) US8465741B2 (enExample)
EP (3) EP2716657A3 (enExample)
JP (3) JP2010513539A (enExample)
KR (2) KR101546441B1 (enExample)
CN (2) CN103709249B (enExample)
AU (1) AU2007338607B2 (enExample)
BR (1) BRPI0720565A2 (enExample)
CA (2) CA2673725C (enExample)
MX (1) MX2009006659A (enExample)
WO (2) WO2008076487A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673725C (en) * 2006-12-20 2016-01-12 Mmr Information Systems, Inc. Antibodies and methods for making and using them
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
AR080301A1 (es) 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
US8481688B2 (en) * 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
CN105924519B (zh) 2010-12-31 2019-08-23 生物蛋白有限公司 全面单克隆抗体产生
MX344595B (es) * 2010-12-31 2016-12-20 Bioatla Llc Humanizacion rapida de anticuerpos.
EP2673635A4 (en) * 2011-02-07 2015-08-12 Neotope Biosciences Ltd IMMUNOTHERAPY THROUGH APOE
PL2694106T3 (pl) 2011-04-01 2018-06-29 Immunogen, Inc. Sposoby zwiększania skuteczności terapii przeciwnowotworowej opartej na receptorze folr1
AU2012328819B2 (en) 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
CN104010659A (zh) * 2011-12-19 2014-08-27 洛克菲勒大学 非唾液酸化的抗炎多肽
US12384848B2 (en) 2011-12-19 2025-08-12 The Rockefeller University Anti-inflammatory polypeptides
KR20150046316A (ko) 2012-08-31 2015-04-29 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
US10117933B2 (en) 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
PT3038650T (pt) 2013-08-30 2021-08-25 Immunogen Inc Anticorpos e ensaios para a deteção do recetor de folato 1
AU2016226115B2 (en) 2015-03-04 2021-03-25 The Rockefeller University Anti-inflammatory polypeptides
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン, インコーポレイテッド 抗folr1免疫複合体を含む治療組み合わせ
EP3481862A4 (en) * 2016-07-06 2020-08-12 Celgene Corporation LOW IMMUNOGENIC ANTIBODIES AND USES THEREOF
MA47691A (fr) * 2017-08-03 2020-01-08 Alector Llc Anticorps anti-cd33 et leurs procédés d'utilisation
US20210213118A1 (en) * 2018-08-31 2021-07-15 Immune Biosolutions Inc Antibodies specific for ntsr1 and uses thereof
CN111662382A (zh) * 2019-03-06 2020-09-15 瑞阳(苏州)生物科技有限公司 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用
JP7370569B2 (ja) * 2019-08-07 2023-10-30 国立大学法人 大分大学 アミロイドβタンパク質オリゴマーと結合するヒト化抗体
JP7791836B2 (ja) * 2020-04-24 2025-12-24 メモリアル スローン ケタリング キャンサー センター 抗cd3抗体及びその使用
CA3202768A1 (en) * 2020-12-07 2022-06-16 Totient, Inc. Systems and methods for producing disease-associated protein compositions
WO2025024323A1 (en) * 2023-07-21 2025-01-30 Bighat Biosciences, Inc. P- and e-selectin-binding compositions and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
ES2145004T3 (es) * 1991-08-21 2000-07-01 Novartis Ag Derivados de anticuerpos.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP2000169393A (ja) * 1998-09-30 2000-06-20 Sankyo Co Ltd 抗Fas抗体を含有する医薬
PE20011338A1 (es) 2000-05-26 2002-01-13 Bristol Myers Squibb Co Moleculas mutantes de ctla4 solubles
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
RU2004127458A (ru) * 2002-02-14 2005-10-27 Иммуномедикс, Инк. (Us) Анти-cd20 антитела, их гибридные белки и способы их использования
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
DK1629011T3 (da) * 2003-05-31 2010-05-03 Micromet Ag Humane anti-humane-DC3-bindingsmolekyler
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
ZA200601699B (en) * 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
PT1692182E (pt) * 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
EP1735000A2 (en) * 2004-04-16 2006-12-27 Genentech, Inc. Method for augmenting b cell depletion
EP1773393A2 (en) 2004-05-05 2007-04-18 Genentech, Inc. Preventing autoimmune disease by using an anti-cd20 antibody
EA012464B1 (ru) * 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1869192B1 (en) * 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
KR20080031001A (ko) * 2005-06-02 2008-04-07 아스트라제네카 아베 Cd20에 대한 항체 및 그의 용도
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US10155816B2 (en) * 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2673725C (en) 2006-12-20 2016-01-12 Mmr Information Systems, Inc. Antibodies and methods for making and using them

Similar Documents

Publication Publication Date Title
JP2021191763A5 (enExample)
JP2022512132A5 (enExample)
JP2020180158A5 (enExample)
JP2009225799A5 (enExample)
JP2008542278A5 (enExample)
JP2022037133A (ja) 改良された血清アルブミン結合剤
JP2017501711A5 (enExample)
JP2021503455A5 (enExample)
JP2020525032A5 (enExample)
JP2010536384A5 (enExample)
JP2024532485A5 (enExample)
JP2010534478A5 (enExample)
JP2018526981A5 (enExample)
JP2011207882A5 (enExample)
JP2013517330A5 (enExample)
JP2014511179A5 (enExample)
JP2017533694A5 (enExample)
JP2017507652A5 (enExample)
JP2012504955A5 (enExample)
JP2013506428A5 (enExample)
JP2016516400A5 (enExample)
JP2011517447A5 (enExample)
JP2024541680A5 (enExample)
JP2023509390A5 (enExample)
JP2018518940A5 (enExample)